Table 2.
Correlation of IL2RA mRNA expressions with cytogenetical and genetic abnormalities in AML
| Cytogenetical and genetic abnormalities | N/Total | Low IL2RA mRNA expression | High IL2RA mRNA expression | p-value |
|---|---|---|---|---|
| CBF | 54/239 | 45/191 | 9/48 | 0.565 |
| Intermediate-risk | 148/239 | 118/191 | 30/48 | 1.000 |
| Poor-risk | 39/239 | 29/191 | 9/48 | 0.505 |
| t(8;21);RUNX1-RUNX1T1 | 37/239 | 29/191 | 8/48 | 0.824 |
| inv(16) or t(16;16);CBFB-MYH11 | 17/239 | 16/191 | 1/48 | 0.207 |
| t(9;11);MLLT3-KMT2A | 4/239 | 4/191 | 0/48 | 0.586 |
| t(6;9);DEK-NUP214 | 3/239 | 2/191 | 1/48 | 0.491 |
| inv(3) or t(3;3);GATA2, MECOM | 6/239 | 4/191 | 2/48 | 0.347 |
| 11q23; non t(9;11) | 3/239 | 3/191 | 0/48 | 0.700 |
| t(16;21);FUS-ERG | 2/239 | 0/191 | 2/48 | 0.040 |
| −7/7q− | 11/239 | 7/191 | 4/48 | 0.238 |
| −5/5q− | 5/239 | 4/191 | 1/48 | 1.000 |
| Complex | 17/239 | 12/191 | 5/48 | 0.346 |
| Normal karyotype | 113/239 | 92/191 | 21/48 | 0.630 |
| Trisomy | 17/239 | 13/191 | 4/48 | 0.754 |
| FLT3-ITD+ | 38/192 | 17/151 | 21/41 | < 0.001 |
| NPM1+ | 36/192 | 28/151 | 8/41 | 1.000 |
| NPM1+FLT3-ITD− | 22/192 | 22/151 | 0/41 | 0.005 |
| CEBPADM+ | 19/192 | 18/151 | 1/41 | 0.082 |
| c-KIT D816V+ | 7/192 | 6/151 | 1/41 | 1.000 |
N: number